Abstract 1905P
Background
Tertiary lymphoid structures (TLS) are organized aggregates of immune cells that form postnatally in non-lymphoid tissues and arise under physiological conditions. However, the clinical and immunological implications of heterogeneous subpopulations of TLS in clear cell renal cell carcinoma (ccRCC) remain to be elucidated.
Methods
H&E, immunohistochemistry and 12-marker multispectral fluorescent were used to evaluate the spatial location and maturation status of TLS with TME cell-infiltrating characterizations. We comprehensively assessed the prognostic value of TLS heterogeneity in 395 patients with ccRCC from two independent cohorts using log-rank tests, Cox hazards models, and scoring nomograms. Associations between TLS heterogeneity and immunologic activity of TME were assessed using quantified lymphocytes infiltration fraction.
Results
By pathological review, TLS were identified in 34.2% of the ccRCC samples. For ccRCC patients, the presence of intratumoral TLS markedly correlated with both superior progression-free survival (PFS) and overall survival (OS), while the peritumoral TLS exerted the opposite predictive trend of clinical outcomes. Multivariate Cox analysis revealed that the presence of intratumoral TLS was prominently correlated with better outcomes. Additionally, the novel nomograms incorporating the presence of intratumoral TLS prominently predicted the probability of 8-year PFS and OS of ccRCC (AUC >0.80). Moreover, a higher proportion of early TLS was found in peritumoral TLS (P=0.016), while intratumoral TLS were mainly composed of secondary follicle-like TLS (P=0.004). Interestingly, in ccRCC samples with the presence of peritumoral TLS enriched with primary follicle-like TLS, the proportion of PD-L1+ tumor-associated macrophages and Treg infiltration in the stroma were prominently increased, showing a typical suppressive tumor immune microenvironment.
Conclusions
In conclusion, this study revealed the predictive value of TLS heterogeneity on the progression and immunological responses of ccRCC for the first time. The intratumoral TLS could be used to assess both the prognostic patterns and the unique TME characteristics of each patient.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1756P - Vizcan: A Swedish population-based study to address cancer outcomes using an interactive platform
Presenter: Anders Berglund
Session: Poster session 23
1757P - A real-world evaluation of the effectiveness of thermogram along with clinical breast examination in community-based breast cancer screening program
Presenter: Rahul Ravind
Session: Poster session 23
1758P - Body composition meets precision medicine: The prognostic value of sarcopenia in patients (pt) treated with Molecularly Targeted Agents (MTA)
Presenter: Cinta Hierro
Session: Poster session 23
1760P - Systematic review of quality of life (QoL) inclusion among endpoints, reporting and impact of QoL results in phase III non-inferiority trials of systemic treatments in oncology
Presenter: Jessica Paparo
Session: Poster session 23
1761P - Incidence of herpes zoster in cancer patients in Europe: A systematic review
Presenter: Inga Posiuniene
Session: Poster session 23
1762P - Are published data up-to-date? Analysis of time to publication in major oncological journals
Presenter: Pawel Sobczuk
Session: Poster session 23
1763P - The challenge for Cancer Trials Ireland (CTI) to sponsor NCI and non-EU sponsored trials in the EU
Presenter: Eibhlin Mulroe
Session: Poster session 23
1886P - Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601)
Presenter: Craig Gedye
Session: Poster session 23
1887P - Adjuvant everolimus (EVE) in patients (pts) with completely resected very high-risk renal cell cancer (RCC) and clear cell histology: Results from the phase III SWOG S0931 (EVEREST) trial
Presenter: Primo Lara
Session: Poster session 23